Alexios Alexiou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexios Alexiou has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Anastasia Bothou
Department of Midwifery, School of Health Sciences, University of West Attica (UNIWA), 12243 Egaleo, Greece
2 shared publications - Anna Chalkidou
Department of Obstetrics and Gynecology, Democritus University of Thrace, 68100 Alexandropoulis, Greece
2 shared publications - Georgios Iatrakis
Department of Midwifery, School of Health & Care Sciences, University of West Attica, 12243 Athens, Greece
2 shared publications - Konstantinos Nikolettos
Department of Gynaecological Oncology, Maidstone and Tunbridge Wells NHS Trust, Maidstone ME16 9QQ, UK
2 shared publications - Nikolaos Nikolettos
Department of Obstetrics and Gynecology, Democritus University of Thrace, 69100 Alexandroupolis, Greece
2 shared publications - Panagiotis Tsikouras
Department of Obstetrics and Gynecology, Faculty of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece
2 shared publications
Latest Publications
- Open Access
- 19 January 2024
- Published by IntechOpen
The Contribution of Isoflavones in Menopausal Symptomatic as Alternative Treatment Option
Menopause should be treated as a state of alteration of estrogen metabolism. It is characterized by a decrease in progesterone and an increase in estrogen followed by a drop in estrogen. The purpose of this study is to investigate the activity of hyaluronic acid 120 mg and isoflavones MF11RCE 80 mg, in the recovery of the symptoms of menopause and the treatment of its secondary complications such as osteoporosis, urogenital atrophy and accompanying urinary incontinence and vasomotor syndrome MF11RCE isoflavones are widely used to treat various disorders related mainly to women’s health and mainly osteoporosis and menopausal discomforts, based on epidemiological studies that brought the above diseases to a lower percentage, in populations with a high consumption of these plant estrogens. Isoflavones are derived from plants and structurally or functionally resemble endogenous-natural estrogens and their active metabolites. Therefore, they have significant estrogenic (agonistic/antagonistic) activity.
- 19 January 2024
- Published by IntechOpen
Open AccessThe Contribution of Isoflavones in Menopausal Symptomatic as Alternative Treatment Option
Menopause should be treated as a state of alteration of estrogen metabolism. It is characterized by a decrease in progesterone and an increase in estrogen followed by a drop in estrogen. The purpose of this study is to investigate the activity of hyaluronic acid 120 mg and isoflavones MF11RCE 80 mg, in the recovery of the symptoms of menopause and the treatment of its secondary complications such as osteoporosis, urogenital atrophy and accompanying urinary incontinence and vasomotor syndrome MF11RCE isoflavones are widely used to treat various disorders related mainly to women’s health and mainly osteoporosis and menopausal discomforts, based on epidemiological studies that brought the above diseases to a lower percentage, in populations with a high consumption of these plant estrogens. Isoflavones are derived from plants and structurally or functionally resemble endogenous-natural estrogens and their active metabolites. Therefore, they have significant estrogenic (agonistic/antagonistic) activity.
- Open Access
- 1 December 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (12) , 1990
Life Quality in Premenopausal Women after Embolization of Uterine Myomas
Objectives: Fibroids cause significant morbidity and are the most common indication for hysterectomies worldwide, delimiting a major public health problem. Uterine artery embolization (UAE) is an alternative therapy to surgical treatment of symptomatic fibroids; it has satisfactory long-time results and is no longer considered investigational for the treatment of symptomatic fibroids. This study was undertaken to evaluate changes in fibroid specific symptom severity and health-related quality of life (HRQOL) after UAE and to optimize the assessment of safety and outcomes measures for participants who receive UAE to objective compare UAE and surgical alternatives for therapy of symptomatic fibroids. Study design: The analysis was based on questionnaires completed by 270 pre-menopausal females with a mean age of 42 years (range, 38–50 years) who underwent UAE for uterine leiomyomas and/or adenomyosis from November 2013 through December 2019. Only symptomatic women were selected whose symptoms were not improving with medication and who did not wish to have children. The primary outcome measure was a change in fibroid symptoms and HRQOL (health related quality of life) after UAE. Secondary outcomes included the decrease in uterine volume after UAE. Results: Questionnaires were completed by 270 women (100%) at a mean of 12.1 months from UAE. The median follow-up period was two years. Uterine fibroid embolization led to a shrinkage at three months for the 90% of the participants. A reduction of bleeding symptoms, pain and bulk-related symptoms was observed in 89.7%, 88.9%, and 89.5% of the patients, respectively. In the long term, there was no significant difference in parameters assessed compared with the midterm follow-up findings. A total of 6 patients (2.3%) underwent fractional curettage an average of 32.1 months after intervention due to necrotic changes in submucosal fibroids. All participants continued to be satisfied with the intervention, and 240 patients (88.9%) answered that they would recommend uterine fibroid embolization to other patients. Conclusions: Women who undergo UAE have a significant decrease in symptom severity and increase in HRQOL which is associated with high levels of satisfaction with the procedure (even when subsequent therapies are pursued).
- 1 December 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (12) , 1990
Open AccessLife Quality in Premenopausal Women after Embolization of Uterine Myomas
Objectives: Fibroids cause significant morbidity and are the most common indication for hysterectomies worldwide, delimiting a major public health problem. Uterine artery embolization (UAE) is an alternative therapy to surgical treatment of symptomatic fibroids; it has satisfactory long-time results and is no longer considered investigational for the treatment of symptomatic fibroids. This study was undertaken to evaluate changes in fibroid specific symptom severity and health-related quality of life (HRQOL) after UAE and to optimize the assessment of safety and outcomes measures for participants who receive UAE to objective compare UAE and surgical alternatives for therapy of symptomatic fibroids. Study design: The analysis was based on questionnaires completed by 270 pre-menopausal females with a mean age of 42 years (range, 38–50 years) who underwent UAE for uterine leiomyomas and/or adenomyosis from November 2013 through December 2019. Only symptomatic women were selected whose symptoms were not improving with medication and who did not wish to have children. The primary outcome measure was a change in fibroid symptoms and HRQOL (health related quality of life) after UAE. Secondary outcomes included the decrease in uterine volume after UAE. Results: Questionnaires were completed by 270 women (100%) at a mean of 12.1 months from UAE. The median follow-up period was two years. Uterine fibroid embolization led to a shrinkage at three months for the 90% of the participants. A reduction of bleeding symptoms, pain and bulk-related symptoms was observed in 89.7%, 88.9%, and 89.5% of the patients, respectively. In the long term, there was no significant difference in parameters assessed compared with the midterm follow-up findings. A total of 6 patients (2.3%) underwent fractional curettage an average of 32.1 months after intervention due to necrotic changes in submucosal fibroids. All participants continued to be satisfied with the intervention, and 240 patients (88.9%) answered that they would recommend uterine fibroid embolization to other patients. Conclusions: Women who undergo UAE have a significant decrease in symptom severity and increase in HRQOL which is associated with high levels of satisfaction with the procedure (even when subsequent therapies are pursued).